Recent advances in SMA treatments aim to increase the levels of full-length SMN by either upregulating the SMN2 gene or by delivering the SMN1 gene directly to the cells via a viral vector (5). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.